A Phase II Clinical Study to Compare the Efficacy and Safety of Once-Weekly GZR102 Injection and Bi-weekly GZR18 Injection in Type 2 Diabetes Mellitus With Inadequate Glycemic Control on GLP-1 Receptor Agonists, With or Without Oral Antidiabetic Drugs
Latest Information Update: 23 Jul 2025
At a glance
- Drugs Bofanglutide (Primary) ; GZR 102 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Gan&Lee Pharmaceuticals
Most Recent Events
- 23 Jul 2025 New trial record